X
AXSM icon

Xponance’s Axsome Therapeutics AXSM Stock Holding History

Xponance’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
7,133
+3,232
+83% +$701K 0.01% 632
2026
Q1 		$659K Buy
3,901
+636
+19% +$110K ﹤0.01% 901
2025
Q4 		$596K Buy
3,265
+76
+2% +$10.6K ﹤0.01% 885
2025
Q3 		$387K Buy
3,189
+35
+1% +$3.94K ﹤0.01% 1056
2025
Q2 		$329K Buy
3,154
+263
+9% +$27.8K ﹤0.01% 1097
2025
Q1 		$337K Buy
2,891
+232
+9% +$26.4K ﹤0.01% 1059
2024
Q4 		$225K Buy
2,659
+277
+12% +$25.5K ﹤0.01% 1250
2024
Q3 		$214K Buy
+2,382
New +$208K ﹤0.01% 1226

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Xponance's AXSM Position: Q2 2026 in Review

Xponance increased its Axsome Therapeutics (AXSM) stake by 83% in Q2 2026, buying an estimated $701K and bringing the position to 7,133 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #632.

Xponance first reported a position in AXSM in Q3 2024 and has held it in 8 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Xponance held 7,133 shares of Axsome Therapeutics worth $1.75M as of Q2 2026.
  • Xponance bought 3,232 Axsome Therapeutics shares in Q2 2026, an estimated $701K.
  • Axsome Therapeutics made up 0.01% of Xponance's portfolio in Q2 2026, its #632 holding.
  • Xponance first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.